๐Ÿš€New on Netcapital: Developing a potential treatment for COVID-19 by repurposing an FDA-approved drug

Click to rate this post!
[Total: 0 Your Rating: 0]

New Opportunities

TrippBio is a new biotechnology company focused on developing innovative applications of existing drugs to prevent and treat rogue viruses starting with the SARS-CoV-2 virus that causes COVID-19.

Deal Highlights
Repurposing an FDA approved drug, TD213
Works on therapeutic treatments for respiratory diseases that work with your body’s natural defenses.
The global antivirals market is expected to reach $75 Bn by 2023

Opportunities by Industry

eSports | Backers is restructuring eSports competitions by creating crowd-funded prize pools on the Ethereum blockchain. Fans gain a form of equity in the team during the competition and receive their share of the prize pool when their teams win.
Cryptocurrency | Monetran has developed an asset-backed, redeemable, stable token. Their system is designed to cost 70% less than traditional money transfers, and to cut the time of delivery down from days to a mere 3-5 seconds.

๐Ÿค FinTech | Demand Derivatives Corp. is the parent company for the forthcoming innovative, vertically integrated futures exchange RealDemand Board of Trade (โ€œRealBOTโ„ขโ€) and its dedicated clearing house RealDemand Clearing (โ€œRealClearโ„ขโ€) (upon CFTC and SEC approval) destined to trade the worldโ€™s major assets in a creative new way.


Join Our Newsletter



By Registering, you agree that you've read and accepted our disclaimer, you're at least 18 years old, you consent to the terms presented on the disclaimer, and to receive notifications from us.